There is one clinical trial.
This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.
Description: Area under the curveMeasure: Plasma concentration of TERN-101 - AUC Time: 12 weeks
Description: Maximum observed concentrationMeasure: Plasma concentration of TERN-101 - Cmax Time: 12 weeks
Description: Time to reach maximum measured plasma concentrationMeasure: Plasma concentration of TERN-101 - Tmax Time: 12 weeks
Description: Determination of half-lifeMeasure: Plasma concentration of TERN-101 - t1/2 Time: 12 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports